Phase 1 Study to Evaluate the Safety, Feasibility and Immunologic Correlatives of Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Nivolumab (Primary)
- Indications Kaposi's sarcoma; Skin cancer
- Focus Adverse reactions
- 25 Jun 2024 Arms amended from arm 2 to 3. New expansion cohort (Cohort B-PLUS) added newly. Primary measures DLT and MTD will be measured only for cohort A.
- 02 Aug 2021 Status changed from active, no longer recruiting to completed.
- 17 Feb 2021 Planned End Date changed from 1 Jun 2022 to 30 Jun 2021.